Novel biomarkers identified, confirmed for prostate cancer
DORTMUND, Germany—Protagen AG announced last month that protein biomarkers for prostate cancer had been identified, ones that are potential drug targets for precision medicine strategies. These biomarkers were identified by using Protagen SeroTag technology, in close collaboration with Prof. Helmut Klocker of the Medical University of Innsbruck and Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, and Prof. Mark Rubin of Cornell University and Targos Molecular Pathology GmbH, Kassel. The team measured serum autoantibodies in a liquid biopsy from prostate cancer patients, and confirmed tissue-specific biomarkers via immunohistochemistry.
“It is always a good cross-validation, when two independent methods yield the same result. Validated biomarkers in immune oncology and other immune diseases are a valuable asset. We are very excited to work with Protagen together in this emerging field,” said Dr. Thomas Henkel, CEO of Targos.